Kaldırım, HavvaKürşat, AtalayNacaroğlu, Şenay AşıkYazgan, SerpilKırgız, Ahmet2024-08-042024-08-0420201300-12562717-7149https://doi.org/10.37845/ret.vit.2020.29.19https://search.trdizin.gov.tr/yayin/detay/458645https://hdl.handle.net/11616/89838Purpose: To evaluate the effectiveness of intravitreal injections of dexamethasone (DEX) implant in patients with pseudophakic cystoidmacular edema (PCME) or Irvine-Gass Syndrome (IGS).Material and Methods: Patients with ME secondary to uncomplicated cataract surgery who underwent single intravitreal injections of DEXimplant from January 2015 to January 2017 were retrospectively reviewed. The patients were examined at base-line and day 1, week 1, month1, 3, 6 and 12 after intravitreal injection. All patients underwent a complete ophthalmic evaluation, including biomicroscopy, best-correctedvisual acuity (BCVA), intraocular pressure by applanation tonometry, and central macular thickness (CMT) measurement with a spectraldomainoptical coherence tomography (SD-OCT).Results: Nineteen eyes of 18 patients were evaluated. The alteration of mean BCVA and CMT were statistically signifi cantly better than baselinevalues at fi rst, third, sixth and twelfth months (p< 0.001). At 1st week, 1st month and 3rd month intraocular pressure (IOP) values signifi cantlyhigher than baseline (p=0.001, p=0.006, p=0.001, respectively). At 6th month and 12th month IOP values not signifi cantly different at baseline(p=0.506, p=0.650).Conclusion: Both BCVA and mean CMT had signifi cantly improved from baseline values after treatment with single doz intravitreal DEXimplant in patients with IGS.eninfo:eu-repo/semantics/openAccessIntravitreal Dexamethasone Implant in the Treatment of Pseudophakic Cystoid Macular Edema or Irvine-Gass SyndromeArticle29210511010.37845/ret.vit.2020.29.19458645